Merus to Present at the Jefferies Virtual London Healthcare Conference
Merus (Nasdaq:MRUS), a clinical-stage oncology company, announced that CEO Dr. Bill Lundberg will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 14:40 GMT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Merus (Nasdaq:MRUS), a clinical-stage oncology company, announced that CEO Dr. Bill Lundberg will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 14:40 GMT. A live webcast of the presentation will be accessible on the company's Investors page, with an archived version available for a limited time.
Merus specializes in developing innovative multispecific antibodies known as Biclonics® and Triclonics™ that demonstrate characteristics similar to traditional human monoclonal antibodies.
Details
News Market Reaction – MRUS
The recorded move for MRUS in the trading session of this news was +3.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 14:40 p.m. GMT/9:40 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl/. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and https://twitter.com/MerusNV.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.